Imagine facing ovarian cancer that keeps coming back, leaving you feeling out of options. Recurrent ovarian cancer is tough to treat, often resisting standard therapies and leading to a challenging journey for many women. A new clinical trial is exploring a promising approach using dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells, which are specially designed immune cells that can attack cancer. By matching these cells to specific markers found in patients' tumors, the hope is to enhance their effectiveness and reduce the chance of the cancer evading treatment. This study is currently recruiting participants and aims to assess both the safety and early signs of how well this therapy works. While results are still pending, this could mean a new lifeline for women who have exhausted other treatment options. However, it's important to remember that this is still in the early stages, and more research will be needed to fully understand its benefits and risks. For now, this trial represents a beacon of hope in the ongoing fight against ovarian cancer.
Could New Cell Therapy Change the Game for Women with Recurrent Ovarian Cancer?
Plain Language Summary
What this means for you:
This new therapy could be a game-changer for women with recurrent ovarian cancer, offering renewed hope for better outcomes. What this means for you:
This new therapy could be a game-changer for women with recurrent ovarian cancer, offering renewed hope for better outcomes. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE1/PHASE2
Condition(s): Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Intervention(s): Dual-target CAR-NK cell product (BIOLOGICAL), Lymphodepleting chemotherapy (DRUG), Standard supportive care (OTHER)
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha/FOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.
Detailed: The study has two parts: (1) dose escalation using a standard 3+3 design within each antigen-pair cohort to determine safety and a recommended Phase 2 dose (RP2D), and (2) dose expansion at the RP2D to explore preliminary efficacy and translational biomarkers. Target selection (biomarker assignment): Tumor tissue (archival or fresh biopsy) is evaluated by immunohistochemistry (IHC) and/or flow cytometry for MSLN, FRalpha, and MUC16. Eligibility requires expression of at least two of the three targets above a pre-specified threshold. If all three are positive, a Target Selection Committee assigns the participant to the dual-target pair with the highest combined expression (e.g., H-score or percent positive cells) and acceptable normal-tissue risk.
Treatment schema: Participants receive lym
Primary Outcome(s): Incidence of dose-limiting toxicities (DLTs); Incidence and severity of treatment-emergent adverse events
Enrollment: 36 (ESTIMATED)
Lead Sponsor: Beijing Biotech
Start: 2026-02-04 | Primary Completion: 2027-02-17